TSE:4506Pharmaceuticals
Assessing Sumitomo Pharma (TSE:4506) Valuation As AMCHEPRY Faces Key Parkinson’s Disease Review
Sumitomo Pharma (TSE:4506) is back on investors’ radar after Japan’s Ministry of Health, Labour and Welfare scheduled a February 19 committee review of AMCHEPRY, its allogeneic iPS cell derived therapy for advanced Parkinson’s disease.
See our latest analysis for Sumitomo Pharma.
The upcoming AMCHEPRY review arrives after a volatile few months, with a 10.81% 7 day share price return and a 14.19% 30 day share price decline. At the same time, a very large 1 year total shareholder return of...